While waiting for a vaccine: opportunities for optimization of neonatal group B streptococcal (GBS) disease prevention in Israel
Objective: To quantify effects of different strategies for decreasing neonatal early onset GBS sepsis (EOGBS) in Israel. Study design: A risk allocation model for EOGBS among infants ≥ 35w was adapted to Israeli data. Effects of strategies for antepartum (APS) and intrapartum (IPS) screening, and in...
Gespeichert in:
| Veröffentlicht in: | Journal of perinatology 2019-02, Vol.39 (2), p.331-338 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 338 |
|---|---|
| container_issue | 2 |
| container_start_page | 331 |
| container_title | Journal of perinatology |
| container_volume | 39 |
| creator | Waisman, Dan Gover, Ayala Molad, Michal Kedar, Reuven Rotschild, Avi Benitz, William E. |
| description | Objective:
To quantify effects of different strategies for decreasing neonatal early onset GBS sepsis (EOGBS) in Israel.
Study design:
A risk allocation model for EOGBS among infants ≥ 35w was adapted to Israeli data. Effects of strategies for antepartum (APS) and intrapartum (IPS) screening, and intrapartum (IAP) and/or postpartum antibiotic prophylaxis (PAP) were calculated.
Results:
Estimated EOGBS attack rates (AR) with APS in 90%, IAP in 90%, may reduce AR to 0.18/1000. A rapid intrapartum test would further decrease AR to 0.16/1000, while reducing IAP from 21.3 to 12.5% of women. For babies with risk factors and GBS+ who do not receive IAP, further risk reduction could be achieved by PAP.
Conclusion:
IAP remains the main intervention to decrease EOGBS. IAP and PAP together may reduce EOGBS present incidence by 40%. Combining rapid intrapartum screening with selective IAP and selective PAP for remaining gaps, would be the most efficient strategy. |
| doi_str_mv | 10.1038/s41372-018-0289-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2155172068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A608210677</galeid><sourcerecordid>A608210677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-57677a1912017d45f6a188df9734215bfa2cf9bc913b53db0454538c8b017c3b3</originalsourceid><addsrcrecordid>eNp1kk9rFTEUxYNY7LP6AdxIQJC6mJq_k4y7tmhbKLhQcRkymeS9lHnJmGQquvKjm-mr1oqSQCD3dw73Xg4AzzA6wojK15lhKkiDsGwQkV1DHoAVZqJtOGf0IVghwWgjKWv3weOcrxBaiuIR2KeIU0kJX4Efnzd-tPCr9sWHNXQxQQ2vtTE-2DcwTlNMZQ61aPNNMU7Fb_13XXwMMDoYbAy66BGuU5wneAJzSXYq0URj6u_h2cmHV3Dw2eps4ZTstQ03Uh_gRU7ajk_AntNjtk9v3wPw6d3bj6fnzeX7s4vT48vGMIFKw2vjQuMOE4TFwLhrNZZycJ2gjGDeO02M63rTYdpzOvSIcVZnNLKvvKE9PQCHO98pxS-zzUVtfTZ2HHUdYc6qmnAsCGplRV_8hV7FOYXaXaVEvQKJ7o5a69EqH1wsSZvFVB23SBKMaseVOvoHVc9gt97EYF1d_33Byz8EG6vHsslxnJet5fsg3oEmxZyTdWpKfqvTN4WRWuKhdvFQNR5qiYciVfP8drK539rht-JXHipAdkCupbC26W70_7v-BJ4XwpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2172177079</pqid></control><display><type>article</type><title>While waiting for a vaccine: opportunities for optimization of neonatal group B streptococcal (GBS) disease prevention in Israel</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Waisman, Dan ; Gover, Ayala ; Molad, Michal ; Kedar, Reuven ; Rotschild, Avi ; Benitz, William E.</creator><creatorcontrib>Waisman, Dan ; Gover, Ayala ; Molad, Michal ; Kedar, Reuven ; Rotschild, Avi ; Benitz, William E.</creatorcontrib><description>Objective:
To quantify effects of different strategies for decreasing neonatal early onset GBS sepsis (EOGBS) in Israel.
Study design:
A risk allocation model for EOGBS among infants ≥ 35w was adapted to Israeli data. Effects of strategies for antepartum (APS) and intrapartum (IPS) screening, and intrapartum (IAP) and/or postpartum antibiotic prophylaxis (PAP) were calculated.
Results:
Estimated EOGBS attack rates (AR) with APS in 90%, IAP in 90%, may reduce AR to 0.18/1000. A rapid intrapartum test would further decrease AR to 0.16/1000, while reducing IAP from 21.3 to 12.5% of women. For babies with risk factors and GBS+ who do not receive IAP, further risk reduction could be achieved by PAP.
Conclusion:
IAP remains the main intervention to decrease EOGBS. IAP and PAP together may reduce EOGBS present incidence by 40%. Combining rapid intrapartum screening with selective IAP and selective PAP for remaining gaps, would be the most efficient strategy.</description><identifier>ISSN: 0743-8346</identifier><identifier>EISSN: 1476-5543</identifier><identifier>DOI: 10.1038/s41372-018-0289-2</identifier><identifier>PMID: 30538325</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>692/308/174 ; 692/700/1538 ; Analysis ; Antibiotic Prophylaxis - statistics & numerical data ; Antibiotics ; Babies ; Births ; Disease control ; Disease prevention ; Female ; Gestational age ; Humans ; Incidence ; Infant, Newborn ; Infants ; Infection ; Infectious Disease Transmission, Vertical ; Israel - epidemiology ; Medicine ; Medicine & Public Health ; Neonates ; Neonatology ; Newborn babies ; Newborn infants ; Optimization ; Pediatric Surgery ; Pediatrics ; Penicillin G ; Postpartum ; Pregnancy ; Pregnancy Complications, Infectious - prevention & control ; Prevention ; Prophylaxis ; Quality Improvement Article ; Risk allocation ; Risk analysis ; Risk Factors ; Risk management ; Risk Reduction Behavior ; Screening ; Sepsis ; Streptococcal Infections - prevention & control ; Streptococcus ; Streptococcus agalactiae - classification ; Streptococcus agalactiae - isolation & purification ; Streptococcus infections ; Vaccines ; Vagina ; Womens health</subject><ispartof>Journal of perinatology, 2019-02, Vol.39 (2), p.331-338</ispartof><rights>Springer Nature America, Inc. 2018</rights><rights>COPYRIGHT 2019 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Feb 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-57677a1912017d45f6a188df9734215bfa2cf9bc913b53db0454538c8b017c3b3</citedby><cites>FETCH-LOGICAL-c470t-57677a1912017d45f6a188df9734215bfa2cf9bc913b53db0454538c8b017c3b3</cites><orcidid>0000-0002-6768-0042</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41372-018-0289-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41372-018-0289-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30538325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Waisman, Dan</creatorcontrib><creatorcontrib>Gover, Ayala</creatorcontrib><creatorcontrib>Molad, Michal</creatorcontrib><creatorcontrib>Kedar, Reuven</creatorcontrib><creatorcontrib>Rotschild, Avi</creatorcontrib><creatorcontrib>Benitz, William E.</creatorcontrib><title>While waiting for a vaccine: opportunities for optimization of neonatal group B streptococcal (GBS) disease prevention in Israel</title><title>Journal of perinatology</title><addtitle>J Perinatol</addtitle><addtitle>J Perinatol</addtitle><description>Objective:
To quantify effects of different strategies for decreasing neonatal early onset GBS sepsis (EOGBS) in Israel.
Study design:
A risk allocation model for EOGBS among infants ≥ 35w was adapted to Israeli data. Effects of strategies for antepartum (APS) and intrapartum (IPS) screening, and intrapartum (IAP) and/or postpartum antibiotic prophylaxis (PAP) were calculated.
Results:
Estimated EOGBS attack rates (AR) with APS in 90%, IAP in 90%, may reduce AR to 0.18/1000. A rapid intrapartum test would further decrease AR to 0.16/1000, while reducing IAP from 21.3 to 12.5% of women. For babies with risk factors and GBS+ who do not receive IAP, further risk reduction could be achieved by PAP.
Conclusion:
IAP remains the main intervention to decrease EOGBS. IAP and PAP together may reduce EOGBS present incidence by 40%. Combining rapid intrapartum screening with selective IAP and selective PAP for remaining gaps, would be the most efficient strategy.</description><subject>692/308/174</subject><subject>692/700/1538</subject><subject>Analysis</subject><subject>Antibiotic Prophylaxis - statistics & numerical data</subject><subject>Antibiotics</subject><subject>Babies</subject><subject>Births</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Female</subject><subject>Gestational age</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant, Newborn</subject><subject>Infants</subject><subject>Infection</subject><subject>Infectious Disease Transmission, Vertical</subject><subject>Israel - epidemiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neonates</subject><subject>Neonatology</subject><subject>Newborn babies</subject><subject>Newborn infants</subject><subject>Optimization</subject><subject>Pediatric Surgery</subject><subject>Pediatrics</subject><subject>Penicillin G</subject><subject>Postpartum</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - prevention & control</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>Quality Improvement Article</subject><subject>Risk allocation</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Risk management</subject><subject>Risk Reduction Behavior</subject><subject>Screening</subject><subject>Sepsis</subject><subject>Streptococcal Infections - prevention & control</subject><subject>Streptococcus</subject><subject>Streptococcus agalactiae - classification</subject><subject>Streptococcus agalactiae - isolation & purification</subject><subject>Streptococcus infections</subject><subject>Vaccines</subject><subject>Vagina</subject><subject>Womens health</subject><issn>0743-8346</issn><issn>1476-5543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk9rFTEUxYNY7LP6AdxIQJC6mJq_k4y7tmhbKLhQcRkymeS9lHnJmGQquvKjm-mr1oqSQCD3dw73Xg4AzzA6wojK15lhKkiDsGwQkV1DHoAVZqJtOGf0IVghwWgjKWv3weOcrxBaiuIR2KeIU0kJX4Efnzd-tPCr9sWHNXQxQQ2vtTE-2DcwTlNMZQ61aPNNMU7Fb_13XXwMMDoYbAy66BGuU5wneAJzSXYq0URj6u_h2cmHV3Dw2eps4ZTstQ03Uh_gRU7ajk_AntNjtk9v3wPw6d3bj6fnzeX7s4vT48vGMIFKw2vjQuMOE4TFwLhrNZZycJ2gjGDeO02M63rTYdpzOvSIcVZnNLKvvKE9PQCHO98pxS-zzUVtfTZ2HHUdYc6qmnAsCGplRV_8hV7FOYXaXaVEvQKJ7o5a69EqH1wsSZvFVB23SBKMaseVOvoHVc9gt97EYF1d_33Byz8EG6vHsslxnJet5fsg3oEmxZyTdWpKfqvTN4WRWuKhdvFQNR5qiYciVfP8drK539rht-JXHipAdkCupbC26W70_7v-BJ4XwpA</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Waisman, Dan</creator><creator>Gover, Ayala</creator><creator>Molad, Michal</creator><creator>Kedar, Reuven</creator><creator>Rotschild, Avi</creator><creator>Benitz, William E.</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6768-0042</orcidid></search><sort><creationdate>20190201</creationdate><title>While waiting for a vaccine: opportunities for optimization of neonatal group B streptococcal (GBS) disease prevention in Israel</title><author>Waisman, Dan ; Gover, Ayala ; Molad, Michal ; Kedar, Reuven ; Rotschild, Avi ; Benitz, William E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-57677a1912017d45f6a188df9734215bfa2cf9bc913b53db0454538c8b017c3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>692/308/174</topic><topic>692/700/1538</topic><topic>Analysis</topic><topic>Antibiotic Prophylaxis - statistics & numerical data</topic><topic>Antibiotics</topic><topic>Babies</topic><topic>Births</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Female</topic><topic>Gestational age</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant, Newborn</topic><topic>Infants</topic><topic>Infection</topic><topic>Infectious Disease Transmission, Vertical</topic><topic>Israel - epidemiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neonates</topic><topic>Neonatology</topic><topic>Newborn babies</topic><topic>Newborn infants</topic><topic>Optimization</topic><topic>Pediatric Surgery</topic><topic>Pediatrics</topic><topic>Penicillin G</topic><topic>Postpartum</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - prevention & control</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>Quality Improvement Article</topic><topic>Risk allocation</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Risk management</topic><topic>Risk Reduction Behavior</topic><topic>Screening</topic><topic>Sepsis</topic><topic>Streptococcal Infections - prevention & control</topic><topic>Streptococcus</topic><topic>Streptococcus agalactiae - classification</topic><topic>Streptococcus agalactiae - isolation & purification</topic><topic>Streptococcus infections</topic><topic>Vaccines</topic><topic>Vagina</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Waisman, Dan</creatorcontrib><creatorcontrib>Gover, Ayala</creatorcontrib><creatorcontrib>Molad, Michal</creatorcontrib><creatorcontrib>Kedar, Reuven</creatorcontrib><creatorcontrib>Rotschild, Avi</creatorcontrib><creatorcontrib>Benitz, William E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of perinatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Waisman, Dan</au><au>Gover, Ayala</au><au>Molad, Michal</au><au>Kedar, Reuven</au><au>Rotschild, Avi</au><au>Benitz, William E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>While waiting for a vaccine: opportunities for optimization of neonatal group B streptococcal (GBS) disease prevention in Israel</atitle><jtitle>Journal of perinatology</jtitle><stitle>J Perinatol</stitle><addtitle>J Perinatol</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>39</volume><issue>2</issue><spage>331</spage><epage>338</epage><pages>331-338</pages><issn>0743-8346</issn><eissn>1476-5543</eissn><abstract>Objective:
To quantify effects of different strategies for decreasing neonatal early onset GBS sepsis (EOGBS) in Israel.
Study design:
A risk allocation model for EOGBS among infants ≥ 35w was adapted to Israeli data. Effects of strategies for antepartum (APS) and intrapartum (IPS) screening, and intrapartum (IAP) and/or postpartum antibiotic prophylaxis (PAP) were calculated.
Results:
Estimated EOGBS attack rates (AR) with APS in 90%, IAP in 90%, may reduce AR to 0.18/1000. A rapid intrapartum test would further decrease AR to 0.16/1000, while reducing IAP from 21.3 to 12.5% of women. For babies with risk factors and GBS+ who do not receive IAP, further risk reduction could be achieved by PAP.
Conclusion:
IAP remains the main intervention to decrease EOGBS. IAP and PAP together may reduce EOGBS present incidence by 40%. Combining rapid intrapartum screening with selective IAP and selective PAP for remaining gaps, would be the most efficient strategy.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>30538325</pmid><doi>10.1038/s41372-018-0289-2</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6768-0042</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0743-8346 |
| ispartof | Journal of perinatology, 2019-02, Vol.39 (2), p.331-338 |
| issn | 0743-8346 1476-5543 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2155172068 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | 692/308/174 692/700/1538 Analysis Antibiotic Prophylaxis - statistics & numerical data Antibiotics Babies Births Disease control Disease prevention Female Gestational age Humans Incidence Infant, Newborn Infants Infection Infectious Disease Transmission, Vertical Israel - epidemiology Medicine Medicine & Public Health Neonates Neonatology Newborn babies Newborn infants Optimization Pediatric Surgery Pediatrics Penicillin G Postpartum Pregnancy Pregnancy Complications, Infectious - prevention & control Prevention Prophylaxis Quality Improvement Article Risk allocation Risk analysis Risk Factors Risk management Risk Reduction Behavior Screening Sepsis Streptococcal Infections - prevention & control Streptococcus Streptococcus agalactiae - classification Streptococcus agalactiae - isolation & purification Streptococcus infections Vaccines Vagina Womens health |
| title | While waiting for a vaccine: opportunities for optimization of neonatal group B streptococcal (GBS) disease prevention in Israel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A24%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=While%20waiting%20for%20a%20vaccine:%20opportunities%20for%20optimization%20of%20neonatal%20group%20B%20streptococcal%20(GBS)%20disease%20prevention%20in%20Israel&rft.jtitle=Journal%20of%20perinatology&rft.au=Waisman,%20Dan&rft.date=2019-02-01&rft.volume=39&rft.issue=2&rft.spage=331&rft.epage=338&rft.pages=331-338&rft.issn=0743-8346&rft.eissn=1476-5543&rft_id=info:doi/10.1038/s41372-018-0289-2&rft_dat=%3Cgale_proqu%3EA608210677%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2172177079&rft_id=info:pmid/30538325&rft_galeid=A608210677&rfr_iscdi=true |